Epitope-specific humoral responses to human cytomegalovirus glycoprotein-B vaccine with MF59: Anti-AD2 levels correlate with protection from viremia
The human cytomegalovirus (HCMV) virion envelope protein glycoprotein B (gB) is essential for viral entry and represents a major target for humoral responses following infection. Previously, a phase-2 placebo-controlled clinical trial conducted in solid organ transplant candidates demonstrated that...
| Main Authors: | , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Oxford University Press for the Infectious Diseases Society of America
2018
|
| Subjects: | |
| Online Access: | https://repository.londonmet.ac.uk/1376/1/JID_2018_correctedproof.pdf |
| _version_ | 1804071669634957312 |
|---|---|
| author | Baraniak, Ilona Kropff, Barbara McLean, Gary R. Pichon, Sylvie Piras-Douce, Fabienne Milne, Richard S. B. Smith, Colette Mach, Michael Griffiths, Paul D. Reeves, Matthew B. |
| author_facet | Baraniak, Ilona Kropff, Barbara McLean, Gary R. Pichon, Sylvie Piras-Douce, Fabienne Milne, Richard S. B. Smith, Colette Mach, Michael Griffiths, Paul D. Reeves, Matthew B. |
| author_sort | Baraniak, Ilona |
| collection | LMU |
| description | The human cytomegalovirus (HCMV) virion envelope protein glycoprotein B (gB) is essential for viral entry and represents a major target for humoral responses following infection. Previously, a phase-2 placebo-controlled clinical trial conducted in solid organ transplant candidates demonstrated that vaccination with gB plus MF59 adjuvant significantly increased gB ELISA antibody levels whose titer correlated directly with protection against post-transplant viremia. The aim of the current study was to investigate in more detail this protective humoral response in vaccinated seropositive transplant recipients. We focussed on four key antigenic domains (AD) of gB; AD1, AD2, AD4 and AD5 measuring antibody levels in patient sera and correlating these with post-transplant HCMV viremia. Vaccination of seropositive patients significantly boosted pre-existing antibody levels against the immunodominant region AD1 as well as against AD2, AD4 and AD5. A decreased incidence of viremia correlated with higher antibody titers against AD2 but not with antibody titers against the other three ADs. Overall, these data support the hypothesis that antibodies against AD2 are a major component of the immune protection of seropositives seen following vaccination with gB/MF59 vaccine and identify a correlate of protective immunity in allograft patients. |
| first_indexed | 2024-07-09T03:46:56Z |
| format | Article |
| id | oai:repository.londonmet.ac.uk:1376 |
| institution | London Metropolitan University |
| language | English |
| last_indexed | 2024-07-09T03:46:56Z |
| publishDate | 2018 |
| publisher | Oxford University Press for the Infectious Diseases Society of America |
| record_format | eprints |
| spelling | oai:repository.londonmet.ac.uk:13762020-06-05T09:19:38Z http://repository.londonmet.ac.uk/1376/ Epitope-specific humoral responses to human cytomegalovirus glycoprotein-B vaccine with MF59: Anti-AD2 levels correlate with protection from viremia Baraniak, Ilona Kropff, Barbara McLean, Gary R. Pichon, Sylvie Piras-Douce, Fabienne Milne, Richard S. B. Smith, Colette Mach, Michael Griffiths, Paul D. Reeves, Matthew B. 570 Life sciences; biology The human cytomegalovirus (HCMV) virion envelope protein glycoprotein B (gB) is essential for viral entry and represents a major target for humoral responses following infection. Previously, a phase-2 placebo-controlled clinical trial conducted in solid organ transplant candidates demonstrated that vaccination with gB plus MF59 adjuvant significantly increased gB ELISA antibody levels whose titer correlated directly with protection against post-transplant viremia. The aim of the current study was to investigate in more detail this protective humoral response in vaccinated seropositive transplant recipients. We focussed on four key antigenic domains (AD) of gB; AD1, AD2, AD4 and AD5 measuring antibody levels in patient sera and correlating these with post-transplant HCMV viremia. Vaccination of seropositive patients significantly boosted pre-existing antibody levels against the immunodominant region AD1 as well as against AD2, AD4 and AD5. A decreased incidence of viremia correlated with higher antibody titers against AD2 but not with antibody titers against the other three ADs. Overall, these data support the hypothesis that antibodies against AD2 are a major component of the immune protection of seropositives seen following vaccination with gB/MF59 vaccine and identify a correlate of protective immunity in allograft patients. Oxford University Press for the Infectious Diseases Society of America 2018-03-08 Article PeerReviewed text en cc_by_nd https://repository.londonmet.ac.uk/1376/1/JID_2018_correctedproof.pdf Baraniak, Ilona, Kropff, Barbara, McLean, Gary R., Pichon, Sylvie, Piras-Douce, Fabienne, Milne, Richard S. B., Smith, Colette, Mach, Michael, Griffiths, Paul D. and Reeves, Matthew B. (2018) Epitope-specific humoral responses to human cytomegalovirus glycoprotein-B vaccine with MF59: Anti-AD2 levels correlate with protection from viremia. Journal of Infectious Diseases, 217 (12). pp. 1907-1917. ISSN 1537-6613 10.1093/infdis/jiy102 |
| spellingShingle | 570 Life sciences; biology Baraniak, Ilona Kropff, Barbara McLean, Gary R. Pichon, Sylvie Piras-Douce, Fabienne Milne, Richard S. B. Smith, Colette Mach, Michael Griffiths, Paul D. Reeves, Matthew B. Epitope-specific humoral responses to human cytomegalovirus glycoprotein-B vaccine with MF59: Anti-AD2 levels correlate with protection from viremia |
| title | Epitope-specific humoral responses to human cytomegalovirus glycoprotein-B vaccine with MF59: Anti-AD2 levels correlate with protection from viremia |
| title_full | Epitope-specific humoral responses to human cytomegalovirus glycoprotein-B vaccine with MF59: Anti-AD2 levels correlate with protection from viremia |
| title_fullStr | Epitope-specific humoral responses to human cytomegalovirus glycoprotein-B vaccine with MF59: Anti-AD2 levels correlate with protection from viremia |
| title_full_unstemmed | Epitope-specific humoral responses to human cytomegalovirus glycoprotein-B vaccine with MF59: Anti-AD2 levels correlate with protection from viremia |
| title_short | Epitope-specific humoral responses to human cytomegalovirus glycoprotein-B vaccine with MF59: Anti-AD2 levels correlate with protection from viremia |
| title_sort | epitope specific humoral responses to human cytomegalovirus glycoprotein b vaccine with mf59 anti ad2 levels correlate with protection from viremia |
| topic | 570 Life sciences; biology |
| url | https://repository.londonmet.ac.uk/1376/1/JID_2018_correctedproof.pdf |
| work_keys_str_mv | AT baraniakilona epitopespecifichumoralresponsestohumancytomegalovirusglycoproteinbvaccinewithmf59antiad2levelscorrelatewithprotectionfromviremia AT kropffbarbara epitopespecifichumoralresponsestohumancytomegalovirusglycoproteinbvaccinewithmf59antiad2levelscorrelatewithprotectionfromviremia AT mcleangaryr epitopespecifichumoralresponsestohumancytomegalovirusglycoproteinbvaccinewithmf59antiad2levelscorrelatewithprotectionfromviremia AT pichonsylvie epitopespecifichumoralresponsestohumancytomegalovirusglycoproteinbvaccinewithmf59antiad2levelscorrelatewithprotectionfromviremia AT pirasdoucefabienne epitopespecifichumoralresponsestohumancytomegalovirusglycoproteinbvaccinewithmf59antiad2levelscorrelatewithprotectionfromviremia AT milnerichardsb epitopespecifichumoralresponsestohumancytomegalovirusglycoproteinbvaccinewithmf59antiad2levelscorrelatewithprotectionfromviremia AT smithcolette epitopespecifichumoralresponsestohumancytomegalovirusglycoproteinbvaccinewithmf59antiad2levelscorrelatewithprotectionfromviremia AT machmichael epitopespecifichumoralresponsestohumancytomegalovirusglycoproteinbvaccinewithmf59antiad2levelscorrelatewithprotectionfromviremia AT griffithspauld epitopespecifichumoralresponsestohumancytomegalovirusglycoproteinbvaccinewithmf59antiad2levelscorrelatewithprotectionfromviremia AT reevesmatthewb epitopespecifichumoralresponsestohumancytomegalovirusglycoproteinbvaccinewithmf59antiad2levelscorrelatewithprotectionfromviremia |